Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

PARP inhibition leads to synthetic lethality with key splicing-factor mutations in myelodysplastic syndromes.

British journal of cancer - 1 Jul 2024

Zhang Fangliang, Sun Jianai, Zhang Lei, Li Ruiqi, Wang Yanzhen, Geng Huichao, Shen Chao, Li Ling, Chen Liang

Abstract excerpt

BACKGROUND: Splicing factors are frequently mutated in patients with myelodysplastic syndromes and acute myeloid leukaemia. Recent studies have revealed convergent molecular defects caused by splicing factor mutations, among which R-loop dysregulation and resultant genome instability are suggested as contributing factors to disease progression. On the other hand, understanding how mutant cells survive upon...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Gene Knock-In Techniques
Share to Mice

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Myelodysplastic Syndromes

Share to Poly (ADP-Ribose) Polymerase-1

Share to Poly(ADP-ribose) Polymerase Inhibitors

Share to RNA Splicing

Share to Serine-Arginine Splicing Factors

Share to Synthetic Lethal Mutations

Source

Open in PubMed Open full text

Identifiers

PMID: 38806724
DOI: 10.1038/s41416-024-02729-0
PMCID: PMC11263539

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

PARP inhibition leads to synthetic lethality with key splicing-factor mutations in myelodysplastic syndromes.PMID 38806724Read ↗

R-Loop Accumulation in Spliceosome Mutant Leukemias Confers Sensitivity to PARP1 Inhibition by Triggering Transcription–Replication ConflictsSemantic proximity Read ↗

Spliceosome Mutations Induce R Loop-Associated Sensitivity to ATR Inhibition in Myelodysplastic Syndromes.Semantic proximity Read ↗

Replication stress signaling is a therapeutic target in myelodysplastic syndromes with splicing factor mutations.Semantic proximity Read ↗

PARP1 as a therapeutic target in acute myeloid leukemia and myelodysplastic syndromeSemantic proximity Read ↗

Therapeutic approaches targeting splicing factor mutations in myelodysplastic syndromes and acute myeloid leukemia.Semantic proximity Read ↗

PARP-inhibitor-induced synthetic lethality for acute myeloid leukemia treatmentSemantic proximity Read ↗

Clinical and prognostic profile of SRSF2 and related spliceosome mutations in patients with acute myeloid leukemiaSemantic proximity Read ↗

[RNA splicing dysregulation in hematological malignancies].Semantic proximity Read ↗

The Augmented R-Loop Is a Unifying Mechanism for Myelodysplastic Syndromes Induced by High-Risk Splicing Factor Mutations.Semantic proximity Read ↗

Genome-wide screening identifies cell-cycle control as a synthetic lethal pathway with SRSF2P95H mutation.Semantic proximity Read ↗

A mitochondrial surveillance mechanism activated by SRSF2 mutations in hematologic malignanciesSemantic proximity Read ↗

A mitochondrial surveillance mechanism activated by <i>SRSF2</i> mutations in hematologic malignanciesSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.